Table 3.
Comparison of clinical information based on VTE occurrence.
| Clinical information | VTEa | No VTEa | p |
|---|---|---|---|
| Age (y) | 10.01 ± 3.27 | 9.84 ± 3.91 | 0.62 |
| Gender (female) | 21 (33.33%) | 60 (57.14%) | <0.001 |
| Anticoagulation therapy | 2/34 (5.88%) | 14 (18.92%) | 0.14 |
| Tumor volume (cm2) | 34.54 ± 5.58 | 24.97 ± 9.02 | <0.001 |
| Tumor gradeb | <0.001 | ||
| 3 | 6 (9.52%) | 85 (80.95%) | |
| 4 | 57 (90.48%) | 20 (19.05%) | |
| Gene Expression | |||
| IDH1 MUT | 3 (6.52%) | 17 (22.67%) | <0.001 |
| ATRX + | 5 (10.87%) | 3 (4.00%) | 0.27 |
| EGFR + | 14 (30.43%) | 15 (20.00%) | 0.28 |
| MGMT Methylation | 14 (30.43%) | 25 (33.33%) | 0.90 |
| p53 MUT | 12 (26.09%) | 11 (14.67%) | 0.19 |
| Treatment | |||
| Radiotherapy | 39 (65.00%) | 80 (91.95%) | <0.001 |
| Chemotherapy | 18 (30.00%) | 41 (48.24%) | <0.001 |
| Target Therapies | 4 (6.67%) | 8 (9.20%) | 0.78 |
| Chinese Traditional Medicine | 5 (8.33%) | 6 (6.90%) | 0.77 |
| Prolonged Bed Restc | 45 (86.54%) | 60 (98.36%) | <0.001 |
| Glucocorticoid Therapy | 34 (56.67%) | 30 (32.61%) | <0.001 |
| History of CVCP | 2 (3.33%) | 10 (11.63%) | 0.14 |
VTE, venous thromboembolism; IDH MUT, isocitrate dehydrogenase mutation; ATRX +, alpha-thalassemia/mental retardation syndrome X-linked positive; EGFR +, epidermal growth factor receptor positive; MGMT, O6-methylguanine-DNA methyltransferase; p53, tumor protein p53; CVCP, central venous catheter placement.
a
Categorical variables are presented as percentages, while continuous variables are presented as mean ± standard deviation.
b
According to the retained pathological reports.
c
Bed rest for more than 2 weeks.